Participated · Series A · May 2026

D-CRBN develops an electrified plasma process that uses renewable electricity to convert CO₂-rich off-gases and hydrocarbons into carbon monoxide and syngas, which the company positions as building blocks for sustainable fuels, chemicals, and materials. The technology is claimed to avoid byproducts like carbon black and has been validated at industrial pilot scale with leading partners in the steel and chemicals sectors. D-CRBN collaborates with industrial players across steel, chemicals, energy, and infrastructure and reports multiple demonstration projects advancing toward commercial deployment. The company plans to scale its first industrial demonstration units, expand its engineering and operations teams, and accelerate commercial rollout following its recent Series A. Financially, D-CRBN secured a €17.5 million Series A and previously received a €2.5 million EIC Accelerator grant in 2023. D-CRBN was founded in 2021 and is headquartered in Antwerp.

Participated · Equity · Feb 2026

Axelera AI is a European semiconductor company designing next-generation AI accelerators optimized for energy-efficient inference at the edge. Its Europa and Metis platforms combine custom chips with tightly integrated software, enabling customers to run AI workloads locally within strict power and thermal envelopes while preserving data privacy. The firm has shipped hardware to more than 500 customers across sectors such as defense, public safety, manufacturing, retail, agritech, robotics and security, demonstrating early commercial traction. Axelera’s edge-first architecture tackles escalating energy and cooling constraints that limit conventional data-center AI deployments, positioning the company for the projected $250 billion inference market by 2030. To drive adoption, Axelera operates a Partner Accelerator Network that unites software vendors, model makers, system integrators and solution providers, and it offers the Voyager SDK for easy workflow integration. The new capital will scale manufacturing through TSMC and Samsung, expand customer-success and ecosystem programs, and advance its software tools. Including the latest round, Axelera AI has attracted over $450 million in equity, grants and venture debt since its July 2021 incorporation, making it the most heavily funded AI chip startup in the EU.

Participated · Equity · Dec 2025

Aidoptation, founded in 2025 as a spin-off from the Indy Autonomous Challenge, develops AI-driven autonomous systems that originated on the racetrack and are now being adapted for real-world mobility and defence applications. The company’s flagship product, EdgeDrive, enables highway-speed autonomy above 90 km/h and has already reached Technology Readiness Level 6–7. Aidoptation targets dual-use deployments across commercial automotive, police, first-responder and defence fleets, with plans to expand partnerships in Europe, the United States and Asia. Headquartered at DronePort in Sint-Truiden, Belgium, the startup benefits from a 30-hectare airport business park designed for carbon-free and autonomous-mobility testing. Its newly raised capital strengthens in-house R&D and supports industrialisation of validated technology while anchoring advanced manufacturing capacity in Belgium. The company positions its work as strategically important for NATO-aligned autonomy and aims to lower dependency risks in critical autonomous tech. Prior to the current raise, Aidoptation closed a €5 million seed round in February 2025 led by LRM and Ethias Ventures.

Participated · Equity · Sep 2025

Aukera develops battery energy storage system (BESS) projects, including a project in Romania referenced in recent reporting. The company secured a €48.5 million loan from the International Finance Corporation to support that Romanian BESS project. Public reporting focuses on this project-specific financing and does not provide broader operational or revenue metrics. The disclosed financing indicates Aukera is pursuing project-level capital raises to advance deployment. No information on founding year, headquarters, or past funding rounds was provided in the available article.

Participated · Equity · Sep 2025

Founded roughly a decade ago, Bloomlife offers a wearable patch embedded with sensors that continuously monitors pregnant women to detect conditions such as hypertension and gestational diabetes without hospital visits. After the pandemic, the company pivoted from direct-to-consumer sales to a B2B model, selling through obstetricians and hospitals. Its technology is now prescribed by more than 120 doctors, a number set to grow more than ten-fold through a newly signed agreement with an employer group representing 2,700 gynecologists across 22 U.S. states. To support this expansion, Bloomlife plans to scale its commercial team from about twenty employees to thirty by year-end. The firm believes 120-150 active prescribers are sufficient for breakeven and had previously targeted profitability by mid-next year, but it has delayed that milestone to focus on onboarding the new partners. Bloomlife remains focused on the U.S. market for the next two years, with Europe and Asia as longer-term opportunities. Cumulatively, the company has raised $34 million to date.